Lupin appoints Yashwant Mahadik as President, Global HR
Myequity news service | Date : 10-07-2018 19:30:00 IST
Lupin Limited, global pharmaceutical company today said it has appointed Yashwant Mahadik as President, Global Human Resources.
Yash Mahadik is a seasoned HR professional with nearly three decades of experience across diverse sectors such as consumer and healthcare in global organizations. His last assignment was with Sun Pharmaceuticals as Global Chief Human Resources Officer prior to which he held HR roles with increasing responsibilities at companies like Philips, Johnson & Johnson, AstraZeneca and Colgate Palmolive.
Yash is a renowned thought leader in HR and has collaborated with leading global academicians to conceptualize and execute strategic initiatives in the field of Human Resource Management.
Nilesh Gupta, Managing Director, Lupin Limited said, "Lupin has a tremendous track record of growth over the past decade which has established a solid foundation as a global pharmaceutical major. This is a critical time for the Pharmaceutical Industry and we are delighted to have Yash join Lupin as we transition our business to a Specialty pharmaceutical and Complex Generics major globally. We are confident that Yash will continue to build on our strong HR foundation and help us create a world-class organization ."
Yash Mahadik will be based in Mumbai and will report to Vinita Gupta, Chief Executive Officer, Lupin and Nilesh Gupta, Managing Director, Lupin.About Lupin Limited:
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APls globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 12th and 8th largest generics pharmaceutical company by market capitalization (31st March 2018, Bloomberg) and revenues (3pt Mar 2018, Bloomberg LTM) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT March 2018); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2018).
Lupin Limited closed 0.93% down at Rs 903.00